Biogen’s Opt-In On Roche’s CD20 Drugs Is Gift That Keeps On Giving

Royalties From Blockbuster Portfolio Amount To Billions

 
• By Andrew McConaghie

Roche has enjoyed decades-long success with its string of CD20-targeting drugs – and thanks to a legacy opt-in, so has Biogen.

Biogen
Biogen is looking for ways to prop up its income as Aduhelm fails to deliver • Source: Alamy

More from Business

More from Scrip